Pinkas Jan
Chief Scientific Officer
Pinkas Jan has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Sep 18, 2026.
On the most recent filing, Pinkas Jan is listed as Chief Scientific Officer at CRESCENT BIOPHARMA, INC. Inside the rolling window, Pinkas Jan reported no open-market purchases and 2 open-market sales totaling $35K in CBIO. The largest disclosed transaction in the window is a sale of 1,288 CBIO shares on Jun 22, 2026, worth $23K.
Companies traded
Other insiders at CBIO
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$35K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Pinkas Jan made?
Pinkas Jan has filed 3 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Pinkas Jan trade?
Pinkas Jan has filed SEC Form 4 disclosures for 1 company, including CBIO.
When was Pinkas Jan's most recent SEC Form 4 filing?
Pinkas Jan's most recent SEC Form 4 filing on Tracefour is dated Sep 18, 2026.
What is Pinkas Jan's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Pinkas Jan is listed as Chief Scientific Officer.
What is Pinkas Jan's total buy and sell value in the current window?
Inside the rolling retention window, Pinkas Jan bought $0 and sold $35K based on SEC Form 4 filings.
What was Pinkas Jan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,288 CBIO shares on 2026-06-22, worth $23K, per SEC Form 4 filings.